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s cancer cells traverse collagen-rich extracellular
matrix (ECM) barriers and intravasate, they adopt
a ﬁbroblast-like phenotype and engage unde-
ﬁned proteolytic cascades that mediate invasive activity.
Herein, we ﬁnd that ﬁbroblasts and cancer cells express an
indistinguishable pericellular collagenolytic activity that
allows them to traverse the ECM. Using ﬁbroblasts isolated
from gene-targeted mice, a matrix metalloproteinase
(MMP)–dependent activity is identiﬁed that drives invasion
A
 
independently of plasminogen, the gelatinase A/TIMP-2
axis, gelatinase B, collagenase-3, collagenase-2, or
stromelysin-1. In contrast, deleting or suppressing expres-
sion of the membrane-tethered MMP, MT1-MMP, in ﬁbro-
blasts or tumor cells results in a loss of collagenolytic and
invasive activity in vitro or in vivo. Thus, MT1-MMP
serves as the major cell-associated proteinase necessary
to confer normal or neoplastic cells with invasive activity.
 
Introduction
 
The metastatic spread of tumor cells to distant organs via
hematogeneous routes represents the most important cause of
morbidity and mortality in cancer (Hanahan and Weinberg,
2000; Chambers et al., 2002). In order for malignant cells to
intravasate into the host vasculature, neoplastic cells express a
tissue-invasive phenotype that allows them to infiltrate an
ECM largely composed of a dense, cross-linked meshwork of
type I collagen fibrils (Hay, 1991).
To date, multiple proteinases have been identified that
impact on tumor cell behavior in vivo as a consequence of their
ability to cleave growth factors, growth factor receptors, cell-
associated molecules, or chemokines/cytokines (Egeblad and
Werb, 2002; Turk et al., 2004). However, with specific regard
to tissue-invasive activity the required proteolytic machinery
remains the subject of speculation. Current evidence suggests
that cancer cells negotiate collagenous barriers by mobilizing
redundant proteolytic systems that each serve to dissolve the
interceding matrix, thus precluding a necessary role for any
single proteinase (Brinckerhoff and Matrisian, 2002; Matrisian
et al., 2003). Further, it has been proposed that even if ECM
hydrolysis is inhibited, tumor cells can adopt an amoeboid
phenotype that accommodates tissue trafficking by mechanical
means alone (Friedl and Wolf, 2003).
Although the genomic instability that characterizes the
neoplastic process may allow each distinct cancer cell to adopt
its own unique strategy for negotiating the ECM, recent gene-
profiling studies support a generic program for initiating the
metastatic process (Ramaswamy et al., 2003). Indeed, tissue-
infiltrating cancer cells of multiple origins have been noted to
assume a mesenchymal cell-like phenotype similar to that dis-
played by fibroblasts (Thiery, 2002; Friedl and Wolf, 2003).
Like tumor cells, fibroblasts are also endowed with the ability
to remodel and infiltrate collagen-rich tissues as a function of
their roles in growth, development, wound healing, and inflam-
mation (Grinnell, 2003; Dong et al., 2004). Interestingly, the
proteolytic or nonproteolytic systems engaged by this “profes-
sional” collagen-remodeling cell type also remain undefined,
as does the possibility that normal and neoplastic cells share a
conserved stratagem for invading the ECM.
Herein, we report that fibroblasts and tumor cells are
able to tunnel through dense barriers of cross-linked type I
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collagen in vitro or in vivo via a virtually indistinguishable
proteolytic process that requires matrix metalloproteinase
(MMP) activity. Further, we demonstrate that fibroblasts
deficient for the membrane-anchored metalloproteinase
MT1-MMP are unable to display pericellular collagenolytic
activity and are incapable of expressing a collagen-invasive
phenotype in vitro or in vivo. Likewise, gene silencing of
MT1-MMP in human carcinoma or fibrosarcoma cells simi-
larly results in a complete loss of membrane-associated col-
lagenolytic activity and renders tumor cells unable to in-
filtrate host tissues. These data identify MT1-MMP as a
required pericellular collagenolysin that confers both normal
and neoplastic cells with tissue-invasive activity.
 
Results
 
MMP-dependent invasion by fibroblasts 
and tumor cells
 
After in vitro fibrillogenesis, type I collagen forms a gel-like
network of interlocking fibrils stabilized by intermolecular, al-
dolimine cross-links similar to those generated in vivo (Hay,
1991). When cultured atop this three-dimensional substratum
and exposed to a chemotactic gradient of PDGF-BB in the
presence of serum, fibroblasts invade the collagen gel (Fig. 1
A). Tumor cells of mesenchymal or epithelial origin (e.g., HT-
1080 and SCC-1 cells, respectively) also infiltrate the three-
dimensional collagen barriers over the course of the 4-d culture
period (Fig. 1 D). Coincident with the invasive process, both fi-
broblasts and tumor cells remodel the collagen substratum,
leaving a network of tunnels that crisscross the traversed ma-
trix (Fig. 1, B and E). Significantly, the channels formed are
not the products of mechanical remodeling alone (Sawhney
and Howard, 2002), as tunnel walls are lined by immuno-
detectable collagen denaturation products (Fig. 1 C). Likewise,
expression of the collagen-invasive phenotype by fibroblasts or
tumor cells correlates with the accumulation of type I collagen
degradation products (Fig. 1, F and G).
To identify the class of proteolytic enzymes responsible
for driving this invasive/degradative process, fibroblasts or tu-
mor cells were stimulated in the absence or presence of cys-
teine (E-64d), aspartyl (pepstatin A), serine (SBTI), or MMP
(BB-94) inhibitors (Hiraoka et al., 1998; Hotary et al., 2000).
Under these conditions, the synthetic MMP inhibitor BB-94
alone is able to block invasion (Fig. 1, A and D), tunnel forma-
tion (Fig. 1, B and E), and collagenolysis (Fig. 1, C, F, and G).
Similar results are obtained with breast, pancreatic, or prostate
carcinoma cell lines where BB-94 inhibits invasion and col-
lagen degradation by more than 90% (Fig. S1, available at http:
//www.jcb.org/cgi/content/full/jcb.200408028/DC1). How-
ever, requirement for proteolytic activity during invasion is
confined to physiologically relevant, cross-linked collagen
gels. When matrices are prepared from pepsin-extracted col-
lagen, which, unlike collagen networks assembled in vivo
 
,
 
 can-
not form intermolecular cross-links and are stabilized by non-
covalent forces alone (Snowden and Swann, 1979; Capaldi and
Chapman, 1982), tunnels are no longer observed in the wake of
the migrating cells (Fig. 1 E) and BB-94 does not block fibro-
blast or tumor cell invasion (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200408028/DC1).
 
Fibroblast-mediated pericellular 
collagenolysis
 
As fibroblasts and tumor cells both express collagenolytic ac-
tivity during invasion, efforts were initiated to identify the
proteolytic systems that mediate pericellular degradation.
During matrix remodeling events in vivo
 
,
 
 fibroblasts express
MMP zymogens that can undergo processing to active forms
(Brinckerhoff and Matrisian, 2002). Similar to the repertoire
of MMPs expressed by fibroblasts activated in vivo (Okada et
al., 1997; Bullard et al., 1999; Wu et al., 2002), fibroblasts
stimulated with PDGF atop a three-dimensional collagen sub-
stratum in vitro express MMP-13, MMP-8, MMP-2, MT1-
MMP, MT3-MMP, MMP-3, and MMP-9 as well as the MMP
inhibitor TIMP-2 (Fig. 2 A). Further, wild-type cells process
proMMP-2 to an active form as observed in vivo (Wang et al.,
2000; Fig. 2 A).
When fibroblasts are stimulated atop a bed of rhodamine-
labeled collagen fibrils in the presence of serum, the field of
collagenolytic activity is confined to the cell–matrix interface
where circulating antiproteinases may have limited access (Fig.
1 B). As observed during invasion (Fig. 1), pericellular col-
lagen degradation is likewise sensitive to inhibition by BB-94
or TIMP-2 (Fig. 2, B and C) and unaffected by serine, cysteine,
or aspartyl proteinase inhibitors (not depicted).
Murine fibroblasts potentially degrade subjacent col-
lagen by mobilizing the direct-acting collagenolysins, MMP-
13, MMP-8, MMP-2, or MT1-MMP (Brinckerhoff and Matri-
sian, 2002). In addition, MT1-MMP may also promote
collagenolysis by catalyzing the processing of either pro-
MMP-2, proMMP-8, or proMMP-13 to active enzymes (Hol-
opainen et al., 2003; Seiki et al., 2003). To identify individual
MMPs or MMP cascades that drive the collagenolytic pheno-
type, fibroblasts were isolated from MMP-13–, MMP-8–,
MMP-2–, or MT1-MMP–deleted mice and the ability of rest-
ing or PDGF-stimulated cells to degrade type I collagen
assessed. As shown in Fig. 2 A, each of the knockout cells ex-
press the full repertoire of MMPs detected in wild-type litter-
mate cells, save for the targeted gene product. Though MMP-
13 or MMP-8 are potent collagenolysins (Brinckerhoff and
Matrisian, 2002) and can be detected in fibroblast releasates
(not depicted), fibroblasts null for either of these MMPs de-
grade collagen comparably to control cells in either the ab-
sence or presence of PDGF (Fig. 2, B and C). Similarly, al-
though recent reports posit a preeminent role for MMP-2 in
degradative events after its TIMP-2–dependent activation by
MT1-MMP (Brinckerhoff and Matrisian, 2002; Seiki et al.,
2003), MMP-2
 
 
 
/
 
 
 
 as well as TIMP-2
 
 
 
/
 
 
 
 fibroblasts also mount
normal collagenolytic responses, effectively eliminating a re-
quired role for the MT1-MMP/TIMP-2/MMP-2 axis in this
proteolytic process (Fig. 2, B and C). MMP-3 has been impli-
cated in the activation of both procollagenases and proMMP-9
(Benbow et al., 1999; Ramos-DeSimone et al., 1999), but nei-
ther MMP-3
 
 
 
/
 
 
 
 nor MMP-9
 
 
 
/
 
 
 
 fibroblasts display defects in
the collagenolytic phenotype (Fig. 2, B and C). 
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As fibroblasts null for each of the major secreted collage-
nases degrade collagen in an area restricted to the pericellular
space, we next considered a direct attack by the membrane-
anchored metalloprotease MT1-MMP. Indeed, MT1-MMP–
deleted fibroblasts display an almost complete defect in col-
lagenolytic activity relative to wild-type cells though the cells
express MMP-13, MMP-8, MMP-2, and TIMP-2 comparably
to control fibroblasts and retain a residual ability to process
proMMP-2 to its active form (Fig. 2, A–C), presumably via
MT3-MMP (Hotary et al., 2002). Consistent with a direct role
for MT1-MMP in the collagenolytic phenotype, collagen degra-
dation by wild-type fibroblasts was blocked completely by either
BB-94 or exogenous TIMP-2, MMP inhibitors whose substrate
profile includes the membrane-anchored MMPs (Fig. 2, B and
C), but not by high concentrations of TIMP-1, an MMP inhibitor
that preferentially targets secreted MMPs (not depicted; Hotary
et al., 2002, 2003). The collagenolytic-null phenotype of MT1-
MMP
 
 
 
/
 
 
 
 fibroblasts is reversed by reexpressing full-length
MT1-MMP, but not by an MT1-MMP construct harboring an in-
activating point mutation in the catalytic domain (i.e., MT1-
MMP E
 
240
 
→
 
A; Fig. 2 B). Consistent with the restricted ability of
secreted proteinases to operate effectively in the presence of se-
rum antiproteinases, the collagenolysis-null phenotype of MT1-
MMP
 
 
 
/
 
 
 
 fibroblasts cannot be rescued when cells are transfected
Figure 1. Collagen-invasive and -degrada-
tive activities of fibroblasts and tumor cells. (A)
Transmission electron micrographs of fibro-
blast monolayers cultured atop three-dimen-
sional collagen gels (2.2 mg/ml) with PDGF-
BB (10 ng/ml) in the presence of 10% serum
at the start of the culture period (0 d) or after
6 d in either the absence or presence of 5  M
BB-94. Zones of collagen clearing are observed
in areas surrounding invading cells (middle,
arrows). Double-headed arrow indicates the
position of the underlying gel. Bar, 10  m. (B)
Laser confocal micrographs of rhodamine-
labeled collagen gels (2.2 mg/ml) incubated
with fibroblasts and PDGF in 10% serum for 0
or 6 d in the absence or presence of BB-94.
Bar, 10  m. (C) Immunofluorescent staining of
collagen cross sections reveals zones of dena-
tured collagen (stained green, arrowheads)
surrounding invading fibroblasts (stained red,
arrow) in the absence, but not the presence,
of BB-94. Bar, 100  m. (D) Light micrographs
of SCC-1 monolayers cultured atop collagen
gels (2.2 mg/ml) and stimulated with hepato-
cyte growth factor (HGF; 50 ng/ml) in 10%
serum for 0 or 4 d in the absence or presence
of BB-94. Arrows indicate islands of invasive
cells. Bar, 100  m. (E) HGF-stimulated SCC-1
cells were cultured atop three-dimensional gels
of rhodamine-labeled collagen gels for 4 d in
the presence of 10% serum, and tunneling
behavior was assessed by laser confocal micros-
copy. Tunnels were not observed in the pres-
ence of BB-94. SCC-1 cells (stained with DAPI
and phalloidin) invade rhodamine-labeled,
pepsin-extracted collagen gels without gener-
ating tunnels. (F and G) Fibroblast (F) or tumor
cell (HT1080 and SCC-1; G) invasion and
collagenolytic activities were monitored in
three-dimensional collagen gels (2.2 mg/ml)
supplemented with 10% serum in the absence
or presence of inhibitors for 6 or 4 d, respec-
tively. Results are expressed as the mean   1
SEM of three or more experiments. 
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Figure 2. Fibroblast MMP expression profile and collagenolytic activity. (A, top) RT-PCR analysis of MMP expression of wild-type and null fibroblasts cultured
atop collagen gels in 10% serum for 3 d with PDGF. (bottom) Gelatin zymography of serum-free supernatants recovered from the wild-type, MMP-2
 / ,
TIMP-2
 / , or MT1-MMP
 /  fibroblasts cultured with PDGF alone (Control) or with either TIMP-1 or TIMP-2. Wild-type fibroblasts express pro-MMP-2 (black
arrowhead) and generate mature MMP-2 (white arrowhead) via a TIMP-2-sensitive process. No MMP-2 was detected in MMP-2
 /  cultures, whereas mature
MMP-2 was not generated in the TIMP-2
 /  cultures. The identity of the high Mr gelatinolytic species in the supernatant of TIMP-2
 /  fibroblasts is unknown.
(B and C) Collagenolytic activity of fibroblasts seeded on a type I collagen film as assessed by confocal laser microscopy (B) or hydroxyproline release
(C). Fibroblasts were seeded atop a 100  g/2.2 cm
2 film of rhodamine-labeled collagen and stimulated with PDGF without or with BB-94 in 10% autologous
mouse serum or cultured under serum-free conditions with PDGF in the presence of 20  g/ml of plasminogen for 5 d. (B) Wild-type or MT1-MMP
 / 
fibroblasts were labeled with calcein-AM (green) and DAPI (blue) in the merged images (first, ninth, and last two images in the series). Bar, 100  m. (C)
Hydroxyproline release was monitored in 10% serum without or with PDGF in the absence or presence of TIMP-2. Results are expressed as the mean   1
SEM of three or more experiments. 
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with a fully active, but soluble, form of MT1-MMP (i.e., 
 
 
 
MT1-
MMP; Fig. 2 B). Though mouse adult fibroblasts can express
low levels of a species-specific orthologue of mammalian MMP-1,
termed mColA (Balbin et al., 2001), subjacent proteolysis is not
affected by transfecting wild-type or MT1-MMP
 
 
 
/
 
 
 
 cells with a
mColA expression vector (Fig. 2 B).
Importantly, the inability of MT1-MMP
 
 
 
/
 
 
 
 fibroblasts to
degrade collagen in a serum-containing environment is not due
to a generalized defect in proliferation or the mobilization or
activation of secreted collagenases. Although MT1-MMP can
affect cell proliferation (Hotary et al., 2003), this effect is lim-
ited to three-dimensional growth and, as such, wild-type and
null fibroblasts replicate at indistinguishable rates atop the col-
lagen substratum (at day 5, 2.1 
 
 
 
 0.3 
 
 
 
 10
 
5
 
 and 1.9 
 
 
 
 0.2 
 
 
 
10
 
5
 
 cells for wild-type and MT1-MMP
 
 
 
/
 
 
 
 fibroblasts, respec-
tively). Further, when MT1-MMP
 
 
 
/
 
 
 
 or MT1-MMP
 
 
 
/
 
 
 
 cells
are triggered under serum-free conditions and the medium sup-
plemented with exogenous plasminogen, both wild-type and
null cells extend collagenolytic activity beyond their cell bor-
ders in a manner consistent with the activation of secreted col-
lagenases (Fig. 2 B; Netzel-Arnett et al., 2002) and degrade
collagen comparably (i.e., wild-type and MT1-MMP
 
 
 
/
 
 
 
 fibro-
blasts solubilize 8.7 
 
 
 
 1.1 and 7.9 
 
 
 
 1.0 
 
 
 
g of hydroxyproline,
respectively). Nonetheless, in an antiproteinase-rich milieu that
recapitulates that encountered in vivo, membrane-anchored
MT1-MMP serves as the dominant collagenase.
 
Tumor cell–dependent collagenolysis
 
Tumor cells, like fibroblasts, also express secreted and mem-
brane-anchored MMPs (Seiki et al., 2003) and efficiently de-
grade subjacent collagen via a BB-94–sensitive process (Fig. 3
A). Consistent with a role for MT1-MMP in pericellular col-
lagenolysis, high dose TIMP-1 is unable to block degradation,
whereas proteolysis is inhibited completely by TIMP-2 (Fig. 3
A). To determine directly the role of MT1-MMP in the tumor
cell collagenolytic phenotype, the expression of the membrane-
anchored enzyme was targeted with a siRNA construct in HT-
1080 or SCC-1 cells. As shown in Fig. 3 B, MT1-MMP is
silenced effectively without affecting MMP-2 or MMP-9 ex-
pression, though, as expected, the MT1-MMP–dependent pro-
cessing of proMMP-2 to its active form is suppressed. Further,
like MT1-MMP
 
 
 
/
 
 
 
 fibroblasts, MT1-MMP siRNA-treated can-
cer cells display no defects in two-dimensional proliferation or
migration across collagen-coated surfaces (Fig. S3, available at
http://www.jcb.org/cgi/content/full/jcb.200408028/DC1). How-
ever, in the absence of endogenous MT1-MMP, the pericellular
collagenolytic activity of HT-1080 cells or SCC-1 cells was lost
completely (Fig. 3 C). Further, the inability of MT1-MMP
Figure 3. MT1-MMP regulates collagen-
degradative activity in tumor cells. (A) Degra-
dative activity of HT-1080 cells (5   10
4)
cultured atop a film of rhodamine-labeled type
I collagen (100  g/2.2 cm
2) in the presence
of 10% serum alone (HT-1080; stained with
phalloidin/DAPI), or with BB-94, TIMP-1, or
TIMP-2. Zones of collagen degradation were
monitored by confocal laser microscopy after
3 d. (B) Western blot analysis of MT1-MMP
(top) expression in HT-1080 or SCC-1 cells
before or after electroporation with a 21-bp
MT1-MMP siRNA (MT1-siRNA) or after coelec-
troporation of MT1-siRNA with a mouse MT1-
MMP plasmid (mMT1). Gelatin zymography
(bottom) of serum-free supernatants recovered
from control or MT1-siRNA–treated HT-1080
or SCC-1 cells after 2 d in culture. MMP-2
(72 kD) and MMP-9 (92 kD) expression are
not affected by MT1-siRNA as assessed by
zymography. Control HT-1080 cells generate
pro-MMP-2 (black arrowhead) and mature
MMP-2 (white arrowhead). (C) HT-1080 cells
were either treated with a control-siRNA, MT1-
siRNA, or coelectroporated with MT1-siRNA
and either MMP-1RXKR, MMP-13RXKR, MMP-
2RXKR, or mMT1-MMP expression vectors, cul-
tured for 3 d atop a film of rhodamine-labeled
type I collagen in 10% serum, and zones of
collagen degradation monitored by confocal
laser microscopy. In the top section of the split
image of MT1-siRNA–treated HT-1080 cells,
the phalloidin/DAPI-stained tumor cells are
shown atop the collagen film, whereas the
lower section displays the underlying collagen
layer alone. Results are representative of four
performed. Bar, 100  m. 
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siRNA-treated tumor cells to mediate subjacent collagenolysis is
not reversed when the cells are transfected with chimeric con-
structs of human MMP-1, MMP-13, or MMP-2 that undergo
constitutive processing to active forms (i.e., MMP-1
 
RXKR
 
, MMP-
13
 
RXKR
 
, or MMP-2
 
RXKR
 
 expression vectors; Hotary et al., 2003;
Fig. 3 C). Although siRNAs can potentially induce nonspecific
effects by mediating off-target gene regulation (Scacheri et al.,
2004), collagenolytic activity is restored completely when the
MT1-MMP siRNA-treated tumor cells are transfected with a
mouse MT1-MMP construct that displays only limited homol-
ogy through the human MT1-MMP siRNA-targeted sequence
(Fig. 3 C). Thus, cancer cells, like fibroblasts, rely on MT1-
MMP to express subjacent collagenolytic activity.
 
MT1-MMP regulates the collagen-
invasive phenotype of fibroblasts in vitro 
and in vivo
 
Although fibroblasts and tumor cells both use MT1-MMP as a
pericellular collagenolysin, the invasive phenotype displayed
by cells negotiating three-dimensional ECM barriers is a more
complex form of cellular behavior and conceivably requires
complementation by other proteolytic systems (Murphy and
Gavrilovic, 1999). Hence, monolayers of wild-type and null fi-
broblasts were established atop three-dimensional collagen gels
and the cells exposed to a chemotactic gradient of PDGF.
Under these conditions, MMP-13
 
 
 
/
 
 
 
, MMP-8
 
 
 
/
 
 
 
, MMP-2
 
 
 
/
 
 
 
,
TIMP-2
 
 
 
/
 
 
 
, MMP-3
 
 
 
/
 
 
 
, and MMP-9
 
 
 
/
 
 
 
 fibroblasts each invade
the collagen gels comparably to wild-type cells while degrad-
ing similar amounts of collagen (Fig. 4, A–C). Likewise,
though plasmin can activate secreted MMPs, fibroblasts iso-
lated from plasminogen-null mice and suspended in plasmino-
gen-null sera display an invasive phenotype indistinguishable
from controls (i.e., 98 
 
 
 
 10% of control; 
 
n 
 
  
 
3). Recent papers
have promoted a potential role for the transmembrane serine
prolyl peptidase, fibroblast activation protein/seprase, in col-
lagen remodeling events (Ghersi et al., 2002), but the null fi-
broblasts also retained full invasive activity (i.e., and 95 
 
 
 
 6%
of control; 
 
n
 
 
 
  
 
3). In contrast, MT1-MMP
 
 
 
/
 
 
 
 fibroblasts are
Figure 4. Fibroblast MT1-MMP mediates collagen-invasive activity. (A–C) Wild-type and null fibroblasts were cultured atop type I collagen gels (2.2 mg/ml;
top two rows, 2-D) or within three-dimensional collagen gels (2.2 mg/ml; bottom row) in 10% serum and stimulated with a PDGF gradient (10 ng/ml) for
6 d in the absence or presence of TIMP-2. The arrow to the left of the panels marks the surface of the collagen monolayer or the edge of the embedded island
of fibroblasts. Arrows within the gel indicate positions of invading fibroblasts. Bars, 100  m. Invasion (B) and collagen degradation (C) were quantified in
three-dimensional collagen gels in the presence of 10% wild-type serum save for experiments with MMP-2
 / , MMP-9
 / , or TIMP-2
 /  fibroblasts, where
null serum was isolated from each of the respective mouse strains. Results are expressed as the mean   1 SEM of three or more experiments.MT1-MMP INITIATES TUMOR METASTASIS • SABEH ET AL. 775
unable to express an invasive phenotype over the 6-d culture
period (Fig. 4, A–C). Though cell behavior can be altered when
cells are embedded within, as opposed to cultured atop, a three-
dimensional matrix (Cukierman et al., 2002, Hotary et al.,
2003), MT1-MMP
 /  cells sustain a similar, and complete, de-
ficiency in three-dimensional invasive behavior relative to
wild-type fibroblasts (Fig. 4 A). However, under either two- or
three-dimensional conditions, the MT1-MMP
 /  invasion-null
phenotype is rescued when cells are transfected with an expres-
sion vector encoding wild-type (Fig. 4 A), but not either solu-
ble  MT1-MMP, inactive MT1-MMP E
240→A, mColA, hu-
man MMP-1RXKR, human MMP-13RXKR, or human MMP-2RXKR
(not depicted). However, defects in MT1-MMP
 /  fibroblasts
are confined to the type I collagen substrate as the null cells mi-
grate across collagen-coated surfaces comparably to controls,
exert a normal collagen-contractile response (Fig. S4, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200408028/DC1),
and, as reported previously, invade three-dimensional matrices
of cross-linked fibrin via an MT3-MMP–dependent process
(Hotary et al., 2002).
Although fibroblasts use MT1-MMP to cross barriers of
type I collagen assembled in vitro, the extracellular matrix in
vivo is a more complex mix of collagens, glycosaminoglycans,
glycoproteins, and peptidoglycans (Hay, 1991). To determine
whether or not MT1-MMP likewise regulates tissue-invasive
activity in vivo, wild-type or null fibroblasts labeled with fluo-
rescent nanobeads were applied to the surface of the chicken
chorioallantoic membrane (CAM), a type I collagen-rich ECM
barrier commonly used to study invasive processes (Kim et al.,
1998). As reported previously (Armstrong et al., 1982), wild-
type fibroblasts readily invade the CAM in the course of a 3-d
culture period (Fig. 5 A). Though the pattern of distribution of
the invading fibroblasts is variable between tissue sections and
individual chick CAMs (unpublished data), both the percentage
of fibroblasts that cross the CAM surface and the depth of the
leading front of invasion is highly reproducible. By either of
these criteria, neither MMP-13
 / , MMP-8
 / , MMP-2
 / ,
MMP-3
 / , MMP-9
 / , plasminogen
 / , nor fibroblast activa-
tion protein
 /  fibroblasts display discernible defects in inva-
sive activity (Fig. 5, A and B). In contrast, MT1-MMP-null fi-
Figure 5. CAM invasion by wild-type and
MMP-null fibroblasts. (A) Fibroblasts from
wild-type, MMP-deficient, or FAP-null mice
were labeled with fluorescent microbeads
(green) and seeded atop the CAM of 11-d-old
chicks and cultured for 3 d. Fluorescent micro-
graphs of CAM cross sections demonstrate the
ability of mouse fibroblasts to penetrate the
CAM surface (DAPI-stained, blue nuclei of
chick cells at the CAM surface are highlighted
by arrows). The MT1-MMP
 /  defect was
reversed by transient transfection of MT1-
MMP
 /  cells with MT1-MMP. Results are rep-
resentative of four performed. Bar, 100  m.
(B) Invasion was quantified as the percentage
of wild-type or null fibroblasts that traversed
the CAM surface and the mean depth of inva-
sion of the leading front of three or more fibro-
blasts. Results are expressed as the mean   1
SD of at least three experiments.JCB • VOLUME 167 • NUMBER 4 • 2004 776
broblasts are completely unable to penetrate the CAM surface
unless the cells are transfected with wild-type, but not a MT1-
MMP E
240→A, expression vector (Fig. 5, B and C).
MT1-MMP–dependent tumor cell invasion 
and intravasation
To determine if a required role for MT1-MMP in fibroblast inva-
sion extends to tumor cells, collagen-invasive activity of the
MT1-MMP siRNA-treated cancer cells was assessed in vitro and
in vivo. As shown in Fig. 6, type I collagen invasion and the as-
sociated degradation of the surrounding matrix by HT-1080 or
SCC-1, although unaffected by the control siRNA, are sup-
pressed almost completely by the MT1-MMP siRNA (Fig. 6, A
and B). Validated siRNA-mediated targeting of either tumor cell
MMP-1, MMP-2, or MMP-9 did not affect collagen-invasive ac-
tivity (unpublished data). A role for MT1-MMP in tumor cell in-
vasion was not limited to HT-1080 or SCC-1 cells, as similar re-
sults are obtained when MT1-MMP expression is silenced in
MDA-MB-231, PANC-1, or DU-145 cells where the number of
invasive foci is reduced by more than 75% (Fig. S5, available at
http://www.jcb.org/cgi/content/full/jcb.200408028/DC1). MT1-
MMP siRNA-treated tumor cells retain full ability to invade ei-
ther pepsin-extracted collagen gels devoid of intermolecular
cross-links or fibrin matrices (Fig. S3). Similarly, (though in
contrast with other recent reports; Ueda et al., 2003; Iida et al.,
2004) invasion through Matrigel, an extract of noncross-linked
ECM macromolecules (Kleinman et al., 1982), is unaffected in
MT1-MMP–targeted tumor cells (Fig. S3). However, invasion
through cross-linked collagen matrices and the associated col-
lagenolytic activity are restored fully by transfecting the MT1-
MMP siRNA-treated tumor cells with the mouse MT1-MMP
construct (Fig. 6, A and B).
Unlike fibroblasts, tumor cells transplanted atop the
CAM not only invade the surrounding tissues but gain access
to the host vascular and/or lymphatic beds where human cell
DNA can be detected as Alu sequences via PCR-based assay
on extracts prepared from the lower CAM (Kim et al., 1998).
To determine if MT1-MMP plays a necessary role in driving
cancer cell invasion and intravasation, tumor cells were treated
with either siRNA controls or MT1-MMP siRNA, and the in
vivo phenotype was monitored. After a 3-d incubation period,
HT-1080 and SCC-1 cells treated with siRNA controls readily
invade the CAM surface (Fig. 6 C). The invasive phenotype
was not limited to the chick extracellular matrix, as tumor cells
cultured atop acellular human dermis and explanted onto the
CAM likewise penetrated this type I/III collagen-rich barrier
(Fig. 6 D). After penetrating the CAM interstitium, the tumor
cells further breach the vascular bed and gain entry to the lower
CAM as detected by Alu sequence (Fig. 6 E). In contrast, MT1-
MMP siRNA-treated cells are unable to express invasive activ-
ity and fail to access the lower CAM unless transfected with
mouse MT1-MMP (Fig. 6, C and E). Neither siRNAs directed
against MMP-2 nor MMP-1 inhibit significantly tumor cell
invasion (i.e., percent invasion for control siRNA-, MMP-2
siRNA-, and MMP-1 siRNA-treated HT-1080 cells is 23.9  
6.7%, 22.2   6.3%, and 21.2   2.6%, respectively). These
data support a necessary, if not critical, role for MT1-MMP
in the metastatic process by arming cancer cells with the abil-
ity to invade interstitial tissues and gain access to the host
vasculature.
Discussion
In vivo, cancer cells initiate metastatic behavior by penetrating
the type I collagen-rich ECM, infiltrating vascular or lymphatic
compartments, and disseminating to distant sites (Hanahan and
Weinberg, 2000; Chambers et al., 2002). Multiple proteolytic
systems have been shown to impact on tumor cell behavior in
vivo (Matrisian et al., 2003; Turk et al., 2004), but the identity
of the enzymes that confer tissue-invasive activity remain con-
troversial. As tumor cells engage the proteolytic machinery
necessary to invade surrounding tissues, they adopt a fibroblast-
like morphology—a phenotypic switch that suggests that tumor
cells access purposefully the same gene programs engaged by
normal cells that traffic through the ECM (Thiery, 2002; Friedl
and Wolf, 2003). Herein, we demonstrate that the membrane-
anchored metalloproteinase MT1-MMP serves as the dominant
purveyor of the tissue-invasive activities necessary to support
the trafficking of normal and neoplastic cells through the ECM.
Although fibroblasts as well as tumor cells also mobilize se-
creted collagenases, which may associate with the cell surface
(Dumin et al., 2001; Netzel-Arnett et al., 2002), such binding
interactions were unable to confer these cells with invasive ac-
tivity. Presumably, only MT1-MMP is directed specifically to
sites targeted for degradation by a combination of motifs em-
bedded not only in the transmembrane domain and intracellular
cytosolic tail but also the collagen-binding hemopexin domain
on the extracellular face of the enzyme (Tam et al., 2002; Seiki
et al., 2003). This conclusion should not be construed to suggest
that secreted collagenases are inoperative in vivo. Rather, the
ability of secreted collagenases to resorb bulk tissue would be
restricted to those sites where the antiproteinase shield is over-
whelmed by a relative proteinase excess or inactivated by either
reactive oxidants or proteolytic attack (Weiss, 1989).
The ability of fibroblasts and tumor cells to mobilize a
pericellular collagenase would appear to provide a mechanis-
tic basis for the tunnel tracks we detected in cell-trafficked
collagen matrices. Indeed, the unique ability of MT1-MMP,
rather than secreted MMPs, to drive invasion correlates pre-
cisely with the singular role that the membrane-anchored pro-
teinase plays in pericellular collagenolysis. Although inva-
sion may require MT1-MMP to cleave collagen as well as one
or more cell surface targets in tandem (Seiki et al., 2003), it
should be noted that MT1-MMP-null cells display no defects
in collagen adhesion, collagen-contractile activity, or migra-
tion, and invade three-dimensional gels constructed of cross-
linked fibrin or noncross-linked collagen comparably to wild-
type cells. Furthermore, invasion is inhibited when tumor
cells confront barriers of a collagenase-resistant mutant form
of type I collagen (Ellerbroek et al., 2001; Hotary et al.,
2003). Finally, we have found that invasive activity can be
conferred by a chimeric MT1-MMP construct wherein the
catalytic domain of the wild-type enzyme has been replaced
with that of the “classic” collagenase MMP- 1 (unpublishedMT1-MMP INITIATES TUMOR METASTASIS • SABEH ET AL. 777
data). Together, these results support a model where MT1-
MMP confers fibroblasts and tumor cells with invasive activ-
ity by acting as a membrane-tethered collagenase.
In vivo, tissue-invasive fibroblasts and cancer cells not
only negotiate collagenous barriers, but the more complex
mix of ECM-associated macromolecules that constitute the
interstitial matrix (Hay, 1991). When applied to the CAM
surface, wild-type fibroblasts and cancer cells both cross the
CAM surface and invade the underlying mesenchyme via a
process dependent completely on MT1-MMP—a finding con-
Figure 6. MT1-MMP drives cancer cell invasion and intravasation. (A and B) HT-1080 or SCC-1 cells were incubated alone with TIMP-1, TIMP-2, a 21-bp
MT1-MMP siRNA, or a 21-bp control siRNA and cultured atop a rhodamine-labeled type I collagen gel (2.2 mg/ml) in 10% serum with 50 ng/ml HGF for
3 d. Tunneling behavior of HT-1080 and SCC-1 cells (A) was monitored by confocal laser microscopy (bottom, merged images of phalloidin/DAPI-labeled
SCC-1 cells and the surrounding rhodamine-labeled collagen are shown). Invasive foci and hydroxyproline release for HT-1080 and SCC-1 cells were
quantified as described in B. Where indicated, MT1-MMP siRNA-treated cells were transfected with a mouse MT1-MMP (mMT1-MMP) expression vector
(MT1-siRNA/mMT1). (C) CAM invasion by fluorescent nanobead-labeled HT-1080 or SCC-1 cells incubated alone, electroporated with MT1-siRNA alone,
or coelectroporated with MT1-siRNA and a mMT1-MMP expression vector. Tumor cell invasion was visualized by fluorescent microscopy of CAM cross
sections after a 3-d incubation period. The CAM surface is marked by arrows. Percent invasion for control-siRNA–, MT1-siRNA–, and mMT1-MMP–trans-
fected MT1-siRNA–treated HT-1080 cells was 24   7%, 1   1%, and 25   3%, respectively, and for SCC-1 cells was 15.8   1%, 1   1%, and 16  
4%, respectively (mean   1 SD; n   3). (D) Invasion of human dermal explants by HT-1080 cells after electroporation with a control siRNA or MT1-siRNA
and cultured atop the CAM for 3 d. The percentage of invading cells and invasion depth for control siRNA- and MT1 siRNA-treated HT-1080 cells,
respectively, were 16.9   5.9% and 144.1   47.6  m and 2.9   0.2% and 22.9   10.8  m. (E) Tumor cell intravasation/extravasation was detected
as Alu-sequences by PCR on DNA extracted from the lower CAM for either HT-1080 or SCC-1 cells after a 3-d incubation period. Chick GAPDH
(chGAPDH) serves as the loading control. Results are representative of four experiments performed. Bars, 100  m.JCB • VOLUME 167 • NUMBER 4 • 2004 778
sistent with the ability of MT1-MMP to cleave multiple inter-
stitial collagen types, glycoproteins and proteoglycans (Seiki
et al., 2003). However, carcinoma as well as fibrosarcoma
cells not only invade locally but also intravasate into the
chick vasculature and/or lymphatic bed (Kim et al., 1998).
Despite the more aggressive phenotype of the transformed
cells, the invasive activity of cancer cells is likewise para-
lyzed by silencing MT1-MMP expression. Although the spec-
ificity of siRNA-mediated silencing must be interpreted cau-
tiously (Scacheri et al., 2004), we note that the inhibitory
effects exerted on tumor cells are reversed by reexpressing an
MT1-MMP construct designed to escape siRNA targeting and
that the observed tumor cell phenotype recapitulates that of
MT1-MMP
 /  fibroblasts. Hence, contrary to expectations
that multiple proteolytic systems can confer invasive activity
(Egeblad and Werb, 2002; Matrisian et al., 2003; Turk et al.,
2004), in the absence of MT1-MMP, none of the five cancer
cell lines studied herein are able to mobilize any of their re-
maining repertoire of serine-, cysteine-, aspartyl-, or metallo-
proteinases alone, or in combination with chick proteinases,
to drive invasion or intravasation.
Although our findings highlight the importance of pro-
teolytic remodeling of the ECM during invasion, recent atten-
tion has focused on the ability of tumor cells to potentially ne-
gotiate collagenous barriers by switching to an amoeboid-like
form of movement that is permissive for the proteinase-inde-
pendent patterns of migration more commonly associated with
myeloid cells (Huber and Weiss, 1989; Friedl and Wolf, 2003;
Wolf et al., 2003). However, we note that tumor cell amoeboid
movement was observed in vitro within the confines of three-
dimensional gels constructed from pepsin-extracted collagen
that no longer contains the telopeptide region critical for the
structural integrity of type I collagen gels (Snowden and
Swann, 1979; Capaldi and Chapman, 1982). Similarly, non-
proteolytic systems have been reported to confer tumor cells
with the ability to traverse Matrigel-coated surfaces (Hotary et
al., 2000; Sahai and Marshall, 2003), a noncross-linked
composite of basement membrane-associated macromolecules
(Kleinman et al., 1982). As collagens found in the interstitial
matrix are normally cross-linked in vivo (Hay, 1991), we posit
that MT1-MMP plays a dominant role in most tissue-invasive
processes as MT1-MMP–suppressed tumor cells were unable
to negotiate type I collagen gels, the CAM interstitial matrix,
or human dermis. This conclusion remains at odds with re-
ports that MMP inhibition fails to block tumor cell migration
in vivo (Wolf et al., 2003) and that MT1-MMP
 /  mice de-
velop normally (Holmbeck et al., 1999). First, with respect to
the amoeboid behavior of tumor cells observed in vivo, HT-
1080 cells were treated with reversible MMP inhibitors in
vitro and antiproteinases were washed away before in vivo
analysis (Wolf et al., 2003). Hence, HT-1080 cells would be
free to mobilize MT1-MMP and initiate invasion. Second, we
find that the concentrations of MMP inhibitors required to
block tumor cell migration in our long term in vitro studies are
far higher than those reached in either animal studies or clini-
cal trials (Matrisian et al., 2003). Third, although MT1-
MMP
 /  mice display no discernible defects at birth, the syn-
thesis and maturation of type I collagen fibrils is confined
largely to the postnatal period (Caulfield and Borg, 1979; Mays
et al., 1988). Indeed, we have found that MT1-MMP
 /  fibro-
blasts can navigate through the type I collagen-poor neonatal
dermis, but remain entrapped in the type I collagen-rich dermis
of 4-wk-old mice (unpublished data). Although collagen con-
tent and structure can differ dramatically from tissue to tissue
even during postnatal states (Hay, 1991), gene-expression pro-
files demonstrate that type I collagen is up-regulated consis-
tently at both primary and metastatic sites in a wide variety of
human carcinomas (Ramaswamy et al., 2003). Hence, MT1-
MMP may play a required role for invasion even at sites
where the collagen content of the normal, pre-affected tissue
is low. Further, while our work emphasizes the importance of
MT1-MMP, preliminary studies indicate that MT2-MMP may
also bestow recipient cells with tissue-invasive activity
(Hotary et al., 2000; unpublished data). However, the more re-
stricted pattern of MT2-MMP expression in vivo suggests that
this alternate collagenolysin likely plays a more limited role
than MT1-MMP in regulating the invasive phenotype.
For more than 30 yr, various proteinases have been linked
to tumor invasion, intravasation, or metastasis (Brinckerhoff
and Matrisian, 2002; Matrisian et al., 2003; Turk et al., 2004).
However, with increasing frequency, proteolytic enzymes ap-
pear to regulate tumor cell behavior in an indirect fashion, e.g.,
by solubilizing matrix-bound growth factors, or by process-
ing cadherins, integrins, and chemokines (Egeblad and Werb,
2002; Seiki et al., 2003; Turk et al., 2004). In contrast, our data,
coupled with more recent findings (Hotary et al., 2003), sup-
port a model wherein MT1-MMP functions as a direct-acting,
pro-invasive factor that confers tumor cells with the ability to
penetrate connective tissue barriers, proliferate within the con-
fines of the three-dimensional ECM, and initiate the metastatic
process. Given the widespread distribution of MT1-MMP both
at the invading front of cancer cells and in the surrounding
stroma (Seiki et al., 2003; Hlubek et al., 2004) as well as
the role of tissue-infiltrating fibroblasts in supporting tumor
growth (Dong et al., 2004), we posit that MT1-MMP serves as
the key protease mobilized by normal and neoplastic cells as
they traverse and remodel ECM barriers in the in vivo setting.
Materials and methods
Isolation and culture of mouse skin fibroblasts and human cancer cells
Fibroblasts were isolated from dorsal dermal explants of 2–4-wk-old
mice with targeted deletions in MT1-MMP (Holmbeck et al., 1999),
MMP-2 (Itoh et al., 1998; provided by S. Itohara, RIKEN Brain Science
Institute, Saitama, Japan), MMP-9 (Liu et al., 1998; provided by R.M.
Senior and J.M. Shipley, Washington University, St. Louis, MO), MMP-3
(Mudgett et al., 1998), MMP-8 (Balbin et al., 2003), seprase/fibroblast
activation protein (Niedermeyer et al., 2000; provided by E. Ostermann
and E. Patzelt, Boehringer Ingelheim, Vienna, Austria), plasminogen
(Ploplis et al., 1995; provided by T. Bugge, National Institutes of Health,
Bethesda, MD), or TIMP-2 (Wang et al., 2000) as well as their wild-type
littermates as described previously (Havemose-Poulsen et al., 1998).
MMP-13
 /  fibroblasts were recovered from knockout mice whose char-
acterization will be described elsewhere. Fibroblasts (passage 2–6)
were cultured in DME supplemented with either 10% heat-inactivated
FCS (Atlanta Biologicals) or heat-inactivated mouse sera, 100 U/ml pen-
icillin, 100  g/ml streptomycin, 0.25  g/ml fungizone, and 2 mM L-glu-
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lection), SCC-1 squamous carcinoma cells (provided by T. Carey,
University of Michigan, Ann Arbor, MI), MDA-MB-231 breast carcinoma
cells (American Type Culture Collection), PANC-1 pancreatic carcinoma
cells (American Type Culture Collection), and DU-145 carcinoma cells
(American Type Culture Collection) were cultured as described previ-
ously (Hotary et al., 2003).
RT-PCR analysis
Fibroblasts were cultured atop type I collagen in the presence and absence
of 10 ng/ml PDGF in media supplemented with 10% serum, and total RNA
was isolated using TRIzol reagent (GIBCO BRL). RT-PCR was performed with
1  g of total RNA and 10  M of specific primers (Kim et al., 1998; Hotary
et al., 2002) using One-Step RT-PCR System reagent (Life Technologies). The
identity of each PCR product was confirmed by sequence analysis.
Expression vector construction and transfection
Fibroblasts or tumor cells were transiently transfected with control vector
(PCR3.1 Uni; Invitrogen), mColA, mouse MT1-MMP (gift of M. Seiki, Uni-
versity of Tokyo, Tokyo, Japan), human MT1-MMP, catalytically inactive
human MT1-MMP (EA mutant, Glu 240→Ala), transmembrane-deleted
human MT1-MMP ( MT1-MMP), or expression vectors encoding propro-
tein convertase-activatable forms of human MMP-1, MMP-2, or MMP-13
(MMP-1RXKR, MMP-2RXKR, and MMP-13RXKR) using Fugene6 (Roche) as de-
scribed previously (Hotary et al., 2003).
Collagen degradation assays
Collagen gel films ( 100  g distributed uniformly over an area of 2
cm
2) were incubated with 0.05 M of sodium borate buffer, pH 9.0, for
1 h and labeled with tetramethylrhodamine isocyanate (Molecular Probes)
for 45 min. Fluorescence images of rhodamine-labeled collagen were
captured by confocal microscopy. Fibroblasts or tumor cells (5   10
4)
were added to the collagen monolayer and incubated for either 5 or
3 d, respectively. Where indicated, cells were labeled with either phal-
loidin, calcein-AM, or DAPI (Molecular Probes). Collagen degradation
products were quantified by hydroxyproline release after an ethanol pre-
cipitation step (70% vol/vol; Creemers et al., 1997). Degradation as-
says were performed in the presence of 10% FCS, in autologous mouse
sera (i.e., from wild-type, MMP-2
 / , MMP-9
 / , or TIMP-2
 /  mice) or
where indicated, under serum-free conditions in the presence of 20  g/
ml of plasminogen (Enzyme Research). Results are presented as the
mean   1 SEM of at least three experiments.
Invasion assays
Type I collagen was acid or pepsin extracted from rat or mice tail ten-
dons (Birkedal-Hansen, 1987; Hotary et al., 2000). Alternatively, pepsin-
extracted bovine dermal collagen (Vitrogen; Nutacon) was commercially
obtained. Collagen gels were prepared in 24-mm Transwell dishes (3- m
pore size; Corning, Inc.) with 1 ml of type I collagen used at a final con-
centration of 2.2 mg/ml (Hotary et al., 2000). After gelling (45 min at
37 C), 1.5–2   10
5 cells in media supplemented with either 10% heat-
inactivated FCS or 10% mouse serum (from either wild-type, TIMP-2
 / ,
plasminogen
 / , MMP-2
 / , or MMP-9
 /  mice) were added to the upper
chamber. PDGF-BB (Upstate Biotechnology) was added to the lower com-
partment of the Transwell chambers to initiate fibroblast invasion or 50
ng/ml hepatocyte growth factor (HGF; Genentech, Inc.) to trigger tumor
cell invasion. Where indicated, gels and media were supplemented with
recombinant tissue inhibitor of metalloproteinases (7.5  g/ml TIMP-1 or
2.5  g/ml TIMP-2; Fuji Chemical Industries), the synthetic MMP inhibitor
BB-94 (5  M final concentration in 0.1% DMSO; British Biotechnology),
the cysteine proteinase inhibitor, E-64d (100  M; Sigma-Aldrich), the as-
partate proteinase inhibitor pepstatin A (50  M; Sigma-Aldrich), or the
serine proteinase inhibitors, soybean trypsin inhibitor, SBTI (100  g/ml)
or aprotinin (200  g/ml; Roche). Invasive activity was visualized by
either phase-contrast microscopy or confocal laser microscopy of rho-
damine-labeled type I collagen gels. The number of invading cells per
high powered field and leading front depth of invasion (three or more
cells) were quantified as the mean   1 SEM of at least three experiments
as described previously (Hotary et al., 2002). Collagen degradation was
monitored by hydroxyproline release as described in the section Collagen
degradation assays.
To analyze the three-dimensional invasive activity of fibroblasts or
tumor cells, 10
5 cells were embedded in 100  l of collagen in a 96-well
plate and cultured for 24 h. The collagen-cell plugs were then transferred
to 24-well plates and further embedded in 1 ml of collagen gels and cul-
tured for 7 d. Cell migration from the central plug into the surrounding col-
lagen was monitored by phase-contrast microscopy.
Gelatin zymography and Western blotting
Gelatin zymography for secreted MMP-2 and MMP-9 and Western blot
analysis were performed as described previously (Hotary et al., 2003).
siRNA electroporation
The antisense strand of siRNA was targeted against a 21-nt MT1-MMP
sequence (5 -AACAGGCAAAGCTGATGCAGA-3 ; nt 228–248). The
nucleotide sequence was scrambled to generate a siRNA control se-
quence (5 -AAGTGATCAAGCACCGAAGAG-3 ). hMMP-1, hMMP-2,
and hMMP-9 were targeted using 21-nt sequences (5 -AAGATGTGGACT-
TAGTCCAGA-3 , nt 86–106 for hMMP-1; 5 -AATACCATCGAGACCAT-
GCGG-3 , nt 274–294 for hMMP-2; and 5 -AAGGAGTACTCGACCTG-
TACC-3 , nt 1066–1086 for hMMP-9). siRNA oligonucleotides (QIAGEN)
were introduced into tumor cells (50–100 nM) using a nucleofector kit and
electroporation (Amaxa Biosystems). Using fluorescent oligonucleotides,
 99% of the tumor cells were transfected. 20 h after electroporation,
siRNA knockdown was complete for up to 72 h.
Chick chorioallantoic membrane assays
In vivo fibroblast or cancer cell invasion and intravasation assays were
conducted using 11-d-old chick embryos wherein wild-type or null fibro-
blasts, HT-1080 cells, or SCC-1 cells (10
5 cells labeled with fluoresbrite
45-nm-diam carboxylate microspheres; Polysciences) were seeded atop
the CAM for 3 d as described previously (Kim et al., 1998; Chambers et
al., 2002). The percentage of invading cells was quantified as a function
of the percentage of the total cell-associated fluorescence localized be-
neath the CAM surface in five or more randomly selected fields (Im-
ageQuant [version 5.2]; Molecular Dynamics Inc.). Depth of invasion from
the CAM surface was defined as the leading front of three or more invad-
ing cells in 10 randomly selected fields.
In selected experiments, HT-1080 cells were cultured atop an acel-
lular fragment of human dermis (Alloderm; Life Cell), and then explanted
atop the CAM for 3 d to initiate invasion.
Histology and microscopy
Frozen sections of fibroblast-collagen gel cocultures were incubated with a
polyclonal antibody against the denatured fragment of type-I collagen (gift
of R. Poole, McGill University, Montreal, Canada) as described previously
(Hollander et al., 1995). Collagen gels were prepared for transmission
EM as described previously (Hotary et al., 2002).
Confocal imaging was performed on a laser scanning fluorescent
microscope (model LSM 510; Carl Zeiss MicroImaging, Inc.) equipped
with acquisition software (Version 3.2 Service Pack 2) using either 40  or
63  C-Apochromat (1.2 NA) water immersion objectives at 25 C. Sam-
ples were mounted in fluorescent mounting media (DakoCytomation). Tri-
ple-color imaging of DAPI, Alexa 488-phalloidin or calcein-AM, and
rhodamine-red was obtained at 364 nm, 488 nm, and 543 nm, respec-
tively, for selective excitation.
All other bright-field, fluorescent, or phase-contrast images were
captured using either an upright fluorescent microscope (Leica; 40  objec-
tive/0.7 NA) or inverted microscopy (Leica; 10  objective/0.3 NA), and
digitally acquired using a Spot digital camera (Software v.3.3; Diagnostic
Instruments) at RT. Image-processing software (Photoshop 7; Adobe) was
used to overlay images and to enhance equally image color and clarity.
Online supplemental material
Figs. S1–S5 are available in the online supplemental material. Fig. S1
shows the effects of BB-94 on collagen invasion and degradation by carci-
noma cell lines. Fig. S2 shows the effect of BB-94 on invasion through
three-dimensional gels of pepsinized collagen. Fig. S3 shows the effects of
MT1-MMP siRNA on tumor cell migration, growth, morphology, and inva-
sion. Fig. S4 shows migration and contractile activity of MMP-null fibro-
blasts. Fig. S5 shows type I collagen invasion by MT1-MMP siRNA-treated
carcinoma cells. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200408028/DC1.
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